1型糖尿病诱发肌少症的研究进展

doi:10.16352/j.issn.1001-6325.2024.08.1189

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (8): 1189-1193.doi: 10.16352/j.issn.1001-6325.2024.08.1189

1型糖尿病诱发肌少症的研究进展

彭晴怡, 许岭翎^*

中国医学科学院北京协和医学院北京协和医院内分泌科,北京 100730

收稿日期:2023-10-08 修回日期:2024-03-29 出版日期:2024-08-05 发布日期:2024-07-24
通讯作者: ^*llxwsh@163.com
基金资助:
中央高水平医院临床科研业务费(2022-PUMCH-B-015)

Research progress on the type 1 diabetes induced sarcopenia

PENG Qingyi, XU Lingling^*

Department of Endocrinology, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730, China

Received:2023-10-08 Revised:2024-03-29 Online:2024-08-05 Published:2024-07-24
Contact: ^*llxwsh@163.com

摘要/Abstract

摘要： 1型糖尿病的肌少症患病率明显高于2型糖尿病及非糖尿病患者,尽早对1型糖尿病患者进行肌少症的筛查、诊断和干预治疗对于提高这些患者的生活质量具有重大意义。1型糖尿病患者肌少症的发生可能与胰岛素样生长因子-1减少、炎性因子激活、线粒体功能障碍、晚期糖基化终末产物蓄积等导致骨骼肌功能下降密切相关。目前,1型糖尿病诱发肌少症的发生发展机制并不完全明确,相关新药治疗缺乏数据支持,进一步的深入研究可能给1型糖尿病患者防治肌少症提供新的方向。

关键词: 1型糖尿病, 肌少症, 流行病学, 发病机制, 治疗

Abstract: The prevalence of sarcopenia in type 1 diabetes is higher than that in type 2 diabetes and non-diabetes patients. Screening, diagnosis and intervention of sarcopenia in type 1 diabetes patients as early as possible is of great significance for improving the life quality of these patients. The occurrence of sarcopenia in type 1 diabetes mellitus may be closely related to the decline of skeletal muscle function caused by the decrease of insulin-like growth factor-1, activation of inflammatory factors, mitochondrial dysfunction, and accumulation of advanced glycation end-products. At present, the mechanism of the occurrence and development of sarcopenia induced by type 1 diabetes is not completely clear, and the relevant new drug treatment lacks data support. Further in-depth research may bring a new direction for the prevention and treatment of sarcopenia in type 1 diabetes patients.

Key words: type 1 diabetes mellitus, sarcopenia, epidemiological, pathogenesis, treatment

中图分类号:

R587.1

彭晴怡, 许岭翎. 1型糖尿病诱发肌少症的研究进展[J]. 基础医学与临床, 2024, 44(8): 1189-1193.

PENG Qingyi, XU Lingling. Research progress on the type 1 diabetes induced sarcopenia[J]. Basic & Clinical Medicine, 2024, 44(8): 1189-1193.

参考文献

[1] American Diabetes Association Professional Practice Committee. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022[J]. Diabetes Care, 2022, 45: S17-S38.
[2] Krause MP, Riddell MC, Gordon CS, et al. Diabetic myopathy differs between Ins2Akita^+/- and streptozotocin-induced Type 1 diabetic models[J]. J Appl Physiol (1985), 2009, 106: 1650-1659.
[3] Tan S, Gunendi Z, Meray J, et al. The evaluation of muscle strength and architecture in type 1 diabetes mellitus: a cross-sectional study[J]. BMC Endocr Disord, 2022, 22: 153. doi:10.1186/s12902-022-01062-y.
[4] Chen LK, Woo J, Assantachai P, et al. Asian working group for sarcopenia: 2019 consensus update on sarcope-nia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21: 300-307.e2.
[5] 刘娟,丁清清,周白瑜,等.中国老年人肌少症诊疗专家共识(2021)[J].中华老年医学杂志, 2021,40:943-952.
[6] Mori H, Kuroda A, Yoshida S, et al. High prevalence and clinical impact of dynapenia and sarcopenia in Japanese patients with type 1 and type 2 diabetes: findings from the impact of diabetes mellitus on dynapenia study[J]. J Diabetes Investig, 2021, 12: 1050-1059.
[7] Hiromine Y, Noso S, Rakugi H, et al. Poor glycemic control rather than types of diabetes is a risk factor for sarcopenia in diabetes mellitus: the muscles-dm study[J]. J Diabetes Investig, 2022, 13: 1881-1888.
[8] Feng L, Gao Q, Hu K, et al. Prevalence and risk factors of sarcopenia in patients with diabetes: a meta-analysis[J]. J Clin Endocrinol Metab, 2022, 107: 1470-1483.
[9] Massimino E, Izzo A, Riccardi G, et al. The impact of glucose-lowering drugs on sarcopenia in type 2 diabetes: current evidence and underlying mechanisms[J]. Cells, 2021, 10: 1958. doi:10.3390/cells10081958.
[10] Khin PP, Hong Y, Yeon M, et al. Dulaglutide improves muscle function by attenuating inflammation through OPA-1-TLR-9 signaling in aged mice[J]. Aging, 2021, 13: 21962-21974.
[11] Tanabe H, Hirai H, Saito H, et al. Detecting sarcopenia risk by diabetes clustering: a Japanese prospective cohort study[J]. J Clin Endocrinol Metab, 2022, 107: 2729-2736.
[12] Hata S, Mori H, Yasuda T, et al. A low serum IGF-1 is correlated with sarcopenia in subjects with type 1 diabetes mellitus: findings from a post-hoc analysis of the iDIAMOND study[J]. Diabetes Res Clin Pract, 2021, 179: 108998. doi:10.1016/j.diabres.2021.108998.
[13] Gutefeldt K, Hedman C A, Thyberg ISM, et al. Dysregulated growth hormone-insulin-like growth factor-1 axis in adult type 1 diabetes with long duration[J]. Clin Endocrinol (Oxf), 2018. doi:10.1111/cen.13810.
[14] Ascenzi F, Barberi L, Dobrowolny G, et al. Effects of IGF-1 isoforms on muscle growth and sarcopenia[J]. Aging Cell, 2019, 18: e12954. doi:10.1111/acel.12954.
[15] Scicchitano BM, Pelosi L, Sica G, et al. The physiopathologic role of oxidative stress in skeletal muscle[J]. Mech Ageing Dev, 2018, 170: 37-44.
[16] Bluestone JA, Buckner JH, Herold KC. Immunotherapy: building a bridge to a cure for type 1 diabetes[J]. Science, 2021, 373: 510-516. doi:10.1126/science.abh1654.
[17] Briet C, Bourdenet G, Rogner UC, et al. The spontane-ous autoimmune neuromyopathy in ICOSL^-/- NOD mice is CD4⁺ T-cell and interferon-γ dependent[J]. Front Immunol, 2017, 8: 287. doi:10.3389/fimmu.2017.00287.
[18] Blagov AV, Summerhill VI, Sukhorukov VN, et al. Type 1 diabetes mellitus: inflammation, mitophagy, and mitochondrial function[J]. Mitochondrion, 2023, 72: 11-21.
[19] Romanello V, Sandri M. The connection between the dynamic remodeling of the mitochondrial network and the regulation of muscle mass[J]. Cell Mol Life Sci, 2021, 78: 1305-1328.
[20] Khalid M, Petroianu G, Adem A. Advanced glycation end products and diabetes mellitus: mechanisms and perspectives[J]. Biomolecules, 2022, 12: 542. doi:10.3390/biom12040542.

1型糖尿病诱发肌少症的研究进展

Research progress on the type 1 diabetes induced sarcopenia

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	苏凌峰, 王虎霞, 王延峰, 宋张骏. 慢性压力对乳腺癌发展的影响[J]. 基础医学与临床, 2024, 44(9): 1303-1307.
[2]	夏雨佳, 杨振丽, 刘玉琴. 肿瘤类器官临床前转化研究及应用[J]. 基础医学与临床, 2024, 44(9): 1214-1218.
[3]	王靓, 夏隆阔, 张建民. 脑类器官在药物研发中的研究进展[J]. 基础医学与临床, 2024, 44(9): 1208-1213.
[4]	刘保清, 黄容, 卢艳, 李凯, 张宁, 刘长征, 宋伟. 胃癌类器官在基础研究与临床应用中的进展[J]. 基础医学与临床, 2024, 44(9): 1219-1222.
[5]	刘泽昊, 王乐, 曹延延, 严小桐, 赵欣, 李文辉, 葛胜旺. 河北省手足口疾病流行病学特征及病原学分析[J]. 基础医学与临床, 2024, 44(9): 1279-1283.
[6]	韩迎东, 王嵩, 张昀, 曾学军. 嗜酸性粒细胞增多综合征合并外周动脉栓塞患者的临床特点分析[J]. 基础医学与临床, 2024, 44(8): 1157-1161.
[7]	高艺丹, 蒋雪涵, 张红, 杨沛然. 靶向异常通路的动脉性肺动脉高压新型药物研发[J]. 基础医学与临床, 2024, 44(8): 1088-1093.
[8]	付志刚, 覃佳, 谭江山. 门脉高压性肺动脉高压:诊治进展与挑战[J]. 基础医学与临床, 2024, 44(8): 1068-1073.
[9]	李阳, 朱蕾. 真核延伸因子2激酶是治疗肿瘤的潜在新靶标[J]. 基础医学与临床, 2024, 44(7): 1039-1043.
[10]	段然, 李青原, 冯同. 代谢重编程在特发性肺纤维化发病中的作用[J]. 基础医学与临床, 2024, 44(6): 882-886.
[11]	中国老年保健协会生长发育和性腺疾病分会. 儿童和青少年颅咽管瘤术后内分泌管理专家共识[J]. 基础医学与临床, 2024, 44(5): 585-598.
[12]	高晓倩, 于华惠, 刘圣, 焦晓璐, 吕倩雯, 张铭, 秦彦文. 血尿素氮水平对急性冠状动脉综合征患者PCI术后MACE的预测价值[J]. 基础医学与临床, 2024, 44(5): 606-612.
[13]	傅晨, 李平. 重型再生障碍性贫血治疗的研究进展[J]. 基础医学与临床, 2024, 44(5): 719-723.
[14]	张沥元, 杜函泽, 潘慧. 治疗下丘脑性肥胖的药物研究进展[J]. 基础医学与临床, 2024, 44(5): 729-732.
[15]	刘宛榕, 赵林. 颅内生殖细胞肿瘤的药物治疗[J]. 基础医学与临床, 2024, 44(10): 1350-1356.